Some business awards are wallpaper; this one carries real clinical weight. EY US named Craig Chambliss, CEO and co-founder of Neurelis, its Entrepreneur Of The Year 2026 National Overall Award winner. In a sector where plenty of companies talk grandly about changing lives and then vanish into the regulatory fog, the underlying story matters more than the trophy.
Neurelis was founded in 2007 around a stubborn, practical problem: getting critical therapy to people experiencing seizure clusters when speed and usability can matter enormously. Chambliss reportedly saw both the human stakes and the clumsy reality of existing delivery options. That does not make every corporate claim sacred, obviously. But it does explain why this recognition lands differently than another generic salute to a fast-growing founder.
A Long Haul Before the Applause
The company’s pivotal milestone came in 2020, when the FDA approved its diazepam nasal spray for seizure clusters. Read that timeline again: founded in 2007, approval in 2020. Thirteen years. That is the part young investors and armchair entrepreneurs regularly underestimate. Drug development is not a pitch deck contest. It is formulation work, clinical evidence, regulatory scrutiny, manufacturing, commercial execution, and a thousand chances for the calendar and budget to get ugly.
Neurelis subsequently expanded the treatment’s reach to children as young as 2 years old, according to the announcement. For families confronting epilepsy, a treatment option designed around real-world administration is not some abstract product differentiator. It can change how caregivers manage a frightening event. That deserves a measured tone, not the usual chest-thumping biotech chatter.
Why Sector Watchers Should Notice
Neurelis is not presented here as a public company, and there is no stock ticker to chase. Frankly, that is a relief. This is not an excuse to pretend an award itself creates a tradable catalyst. It does not. Awards do not replace prescribing data, reimbursement progress, competitive positioning, or durable execution. Anyone claiming otherwise is selling smoke.
Still, private-company developments can tell investors plenty about where value is being built in neuroscience. The company describes itself as a fully integrated neuroscience business now focused on unmet needs across epilepsy and other neurological disorders. That phrase needs watching over time. Expansion beyond a core product can be smart, but it can also become a costly detour if management chases every adjacent opportunity. The notes give no revenue, profitability, market-share, pipeline, or financing figures, so there is no honest basis for declaring Neurelis a commercial juggernaut.
What can be said is narrower and more useful: the company cleared a major regulatory hurdle, broadened patient access, and built enough organizational momentum for its founder to stand out from a large national field. EY’s judges selected Chambliss from 209 regional winners representing 184 U.S. companies. That is meaningful peer recognition, even if it is not financial due diligence.
Building a treatment company around an unmet patient need is admirable; proving it can endure is the harder second act.
The Award Field Offers Some Context
EY recognized 13 other national award winners from nine companies across categories including consumer products, retail, financial services, fintech, industrials, technology, and family business. Chambliss took the overall national distinction, placing Neurelis in a broad mix of founders rather than a narrowly medical contest. The program says winners are assessed on entrepreneurial spirit, purpose, growth, and impact. Those are useful lenses, although they are necessarily broad and a little squishy around the edges.
The wider 2026 regional cohort generated more than $78 billion in revenue over the past year, employed over 155,000 people, and posted 50% sales growth across three years, according to EY. Those aggregate figures describe the entire cohort, not Neurelis. That distinction matters. Too many promotional write-ups casually drape group statistics over an individual company. No thanks.
Recognition Is Not a Substitute for Evidence
Chambliss will represent the United States at the World Entrepreneur Of The Year competition, and the award network may offer valuable relationships with investors, mentors, and operating peers. Networks can help, particularly for a company navigating the expensive, maddening maze of specialized healthcare. They cannot magically solve market access or clinical risk.
The more durable takeaway is that Neurelis has spent nearly two decades pursuing a very specific care challenge and reached an FDA-approved outcome after a long slog. That kind of persistence is easy to praise after the fact and brutally hard to finance beforehand. For those watching neuroscience businesses, the case is a reminder to separate glossy innovation language from companies that have actually pushed a therapy through the wall. On the facts available, Neurelis has done the latter. The next question is whether it can keep translating that foundation into broader, sustainable patient impact without losing its discipline.